Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05034848
Other study ID # CHRO-2018-13
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date March 31, 2021
Est. completion date May 19, 2021

Study information

Verified date December 2022
Source Centre Hospitalier Régional d'Orléans
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prevalence of PAD and osteoporosis (OP) both get higher with age. Clinical and epidemiologic evidence have showed an increased cardiovascular risk in OP and bone loss and fragility fractures in patient with cardiovascular disease. This study will examine the relationship between vascular disease in legs and sBMD and vBMD at trabecular and cortical sites and bone microarchitecture.


Description:

The primary goal of our study is to determinate if presence of PAD is associated with lower sBMD and vBMD values at the tibias, assuming that BMD should be more alterate in the predominant vascular impairement site. Our secondary objectives are to : - determine if severity of PAD quantified by ankle brachial index ABI is associated to a decrease of BMD values defined by T-Score at the left hip, spine and legs, but also with volumetric values, assessed by HRpQCT at the non dominant radius and at both tibias. - determine the prevalence of osteoporosis in our population - To evaluate the relationships between ; - lipids and bone parameters - vit D and parathormone with PAD severity - levels of physical activity and both vascular and bone impairments


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date May 19, 2021
Est. primary completion date May 19, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - PAD patients defined by an Ankle brachial index < 0.9 - Written consent - Patient affiliated with a social security organism Exclusion Criteria: - Age < 18 years - Pregnancy or risk of pregnancy - Patients Under guardianship - Patient with known PAD who had been previously treated by surgery or endovascular pathway

Study Design


Intervention

Procedure:
Assessment of BMD by DXA and HRpQCT
DXA : BMD assessment at the left hip, rachis and both legs HRpQCT : Volumic Bone mineral density, cortical and trabecular parameters, at the non dominant radius and legs Biological samples

Locations

Country Name City State
France CHR d'ORLEANS Orleans

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Régional d'Orléans

Country where clinical trial is conducted

France, 

References & Publications (4)

Breban S, Benhamou CL, Chappard C. Dual-energy X-ray absorptiometry assessment of tibial mid-third bone mineral density in young athletes. J Clin Densitom. 2009 Jan-Mar;12(1):22-7. doi: 10.1016/j.jocd.2008.10.009. Epub 2008 Dec 25. — View Citation

Collins TC, Ewing SK, Diem SJ, Taylor BC, Orwoll ES, Cummings SR, Strotmeyer ES, Ensrud KE; Osteoporotic Fractures in Men (MrOS) Study Group. Peripheral arterial disease is associated with higher rates of hip bone loss and increased fracture risk in older men. Circulation. 2009 May 5;119(17):2305-12. doi: 10.1161/CIRCULATIONAHA.108.820993. Epub 2009 Apr 20. — View Citation

Fehervari M, Sarkadi H, Krepuska M, Sotonyi P, Acsady G, Entz L, Lakatos P, Szeberin Z. Bone mineral density is associated with site-specific atherosclerosis in patients with severe peripheral artery disease. Calcif Tissue Int. 2013 Jul;93(1):55-61. doi: 10.1007/s00223-013-9727-5. Epub 2013 Apr 6. — View Citation

Gaudio A, Muratore F, Fiore V, Rapisarda R, Signorelli SS, Fiore CE. Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease. Osteoporos Int. 2015 Jun;26(6):1747-53. doi: 10.1007/s00198-015-3057-6. Epub 2015 Feb 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Bone Mineral Density (BMD) volumic values at the tibias of PAD (Peripheral Artery Disease) patients BMD volumic values are BMD volumetric bone mineral density (mg HA/cm3) Day 0
Secondary Bone Mineral Density (BMD) measurement by DXA Relations between areal BMD results (DXA) at the hip and lumbar spine and the ankle brachial index measured at the two legs. Day 0
Secondary Correlation between microstructural parameters and ankle brachial index results The following micro structural parameters assessed by HRpQCT at both tibias will be :
Dtrab : volumetric trabecular bone mineral density (mg HA/ cm3),
Dinn : inner trabecular bone density (mg HA/cm3),
Dmeta: metatrabecular bone density (mg HA/cm3),
Dcort: volumetric cortical bone mineral density (mg HA/cm3),
D100: total volumetric bone mineral density (mg HA/cm3),
Tb.Th: trabecular thickness (mm),
Tb.N: trabecular number (mm-1);
Tb.Sp: trabecular separation (mm),
Ct.Th: cortical thickness (mm);
Tb1.NSD: intra-distribution individual separation (mm),
BV / TV: trabecular bone volume (%).
Day 0
Secondary Comparison between microstructural parameters at tibias comparison between bone microarchitecture parameters at the tibia: the parameters will be compared between the most severely limb and the contralateral one. Day 0
Secondary Correlation between Lipid and bone parameters We will study the relation between lipidic and bone parameters. Potential correlations between on the one hand (lipid parameters: total and HDL-cholesterol, triglyceridemia, LDL-cholesterol calculation) and on the other hand bone parameters: vBMD volumetric bone mineral density (mg HA/cm3) Ct.BMD: cortical volumetric bone mineral density (mg/cm3); Tb.BMD: trabecular volumetric bone mineral density (mg HA/cm3) Day 0
Secondary Percentage of densitometric osteoporotic patients percentage of densitometric osteoporotic patients in the population Day 0
Secondary Evaluation of risk of fracture The risk of fracture at 10 years will be evaluate by the Fracture Risk Assessment Tool (FRAX) survey.
The FRAX® tool was developed by the then WHO Collaborating Centre for Metabolic Bone Diseases (1991-2010) at the University of Sheffield. It was launched in 2008 following approximately 10 years of meta-analyses of a variety of risk factors for osteoporotic fracture. Although not the only fracture prediction tool available, FRAX® is the only risk calculator which has been calibrated to rates of fracture and mortality per individual country and has been shown to identify a risk amenable to available treatments.
Day 0
Secondary Evaluation of cardiovascular risk Cardiovascular risk assessment using the SCORE tool (Systematic Coronary Risk Estimation).
Four levels of risk are defined:
Very high cardiovascular risk = 10%;
High risk, which includes subjects with major or particularly high risk factors (familial hypercholesterolemia, severe hypertension, etc.) and those with a score between 5 and 10%;
Moderate risk, which concerns patients with a score between 1 and 5%;
Low risk, which includes subjects with a score < 1%;
Day 0
Secondary Correlation between microstructural parameters at tibias and radius comparison between bone microarchitecture at the tibia and of the radius.
The following micro structural parameters assessed by HRpQCT at tibias and radius will be :
Dtrab : volumetric trabecular bone mineral density (mg HA/ cm3),
Dinn : inner trabecular bone density (mg HA/cm3),
Dmeta: metatrabecular bone density (mg HA/cm3),
Dcort: volumetric cortical bone mineral density (mg HA/cm3),
D100: total volumetric bone mineral density (mg HA/cm3),
Tb.Th: trabecular thickness (mm),
Tb.N: trabecular number (mm-1);
Tb.Sp: trabecular separation (mm),
Ct.Th: cortical thickness (mm);
Tb1.NSD: intra-distribution individual separation (mm),
BV / TV: trabecular bone volume (%).
Day 0
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05712395 - The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease N/A
Active, not recruiting NCT04534257 - Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore N/A
Recruiting NCT04511234 - Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Completed NCT02554266 - Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
Completed NCT03921905 - Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
Not yet recruiting NCT06369350 - Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion Early Phase 1
Recruiting NCT04545268 - Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance N/A
Recruiting NCT02389023 - Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery N/A
Completed NCT02563535 - Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia Phase 4
Completed NCT02542267 - In-Stent Restenosis Post-Approval Study N/A
Completed NCT02522884 - Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries N/A
Completed NCT02539940 - Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
Completed NCT02262949 - A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System N/A
Completed NCT02228564 - BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease N/A
Completed NCT02145065 - First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r) N/A
Completed NCT01743872 - Optical Imaging Measurement of Intravascular Solution Efficacy Trial N/A
Recruiting NCT01424020 - Walking Estimated Limitation Calculated by History - Study 2 Phase 4
Active, not recruiting NCT01597453 - NOR-SYS: The Norwegian Stroke in the Young Study N/A